FDA: Diabetes drug may cause unexpected side effects
-Private MD
11/15/2009 - After receiving numerous reports of kidney problems in patients taking a diabetes medication, the U.S. Food and Drug Administration (FDA) issued a warning regarding the drug's prescription information. Between April 2005 and October 2008, the FDA received 78 reports of problems in kidney function in people taking the drug exenatide, sold by pharmacists as Byetta. More>>>
FDA changes prescribing information on popular diabetes mellitus treatment
-The Examiner
11/05/2009 - Some treatment plans for type 2 diabetes may need to be modified, as the FDA has prompted prescribing information changes for the popular drug Byetta. According to the FDA, from April 2005 until October 2008, 78 reports of impaired kidney function was reported. More>>>
FDA Approves New Byetta Label Amid Renal-Failure Reports
-Wall Street Journal
11/04/2009 - The U.S. Food and Drug Administration on Monday said it approved a new label for the diabetes treatment Byetta, made by Eli Lilly & Co. (LLY) and Amylin Pharmaceuticals Inc. (AMLN), amid reports the medicine may cause kidney problems. More>>>
US FDA issues alert on kidney problems with Byetta
-Reuters
11/03/2009 - Patients and doctors should be aware of possible kidney function problems with Eli Lilly and Amylin Pharmaceuticals' Byetta diabetes drug, U.S. health regulators said on Monday. The U.S. Food and Drug Administration received 78 reports of problems with kidney function in patients using Byetta from April 2005 through October 2008. More>>>
FDA Issues Warning for Diabetes Drug: Reports of kidney problems for those using Byetta prompted action
- US News
11/03/2009 - Reports about possible kidney problems, including renal failure, in people taking the diabetes drug exenatide (Byetta) have prompted changes to the drug's prescribing information, the U.S. Food and Drug Administration said Monday. More>>>
FDA: Byetta Label Revised to Include Safety Information on Possible Kidney Problems
-FDA
11/02/2009 - The U.S. Food and Drug Administration today acted on new safety information about possible kidney function problems, including kidney failure, in patients taking Byetta (exenatide), a drug used to treat Type 2 diabetes. From April 2005 through October 2008, the FDA received 78 reports of problems with kidney function in patients using Byetta. More>>>
Diabetes drug from San Diego’s Amylin caught up in Aussie Brouhaha
-xconomy
10/28/2009 - From Australia comes word that San Diego-based Amylin Pharmaceuticals’ biggest drug, exenatide (Byetta), has been caught up in a controversy over a diabetes report co-sponsored by Amylin’s marketing partner, Eli Lilly & Co. More>>>
Diabetes Drug Could Cause Pancreatic Cancer
-NaturalNews
09/26/2009 - The popular diabetes drug sitagliptin (marketed as Januvia) may increase the risk of pancreatic cancer, according to study conducted by researchers from the University of California- Los Angeles and published in the journal Diabetes. More>>>
FDA Unlikely to Approve Byetta Monotherapy Soon
-Diabetes Health
12/16/08- Hopes that the U.S. Food and Drug Administration would move soon to make the diabetes drug Byetta a monotherapy are fading. It now appears that the FDA will extend its review of the drug into 2009. More>>>
Byetta Recall
-US Recall News
12/11/2008- There seems to be a lot of interest from visitors about a possible Byetta Recall so we wanted to provide some information about what is happening with this drug. More>>>
"I Blame Byetta for My Husband's Death"
-LawyersandSettlements
11/23/2008- "My husband was prescribed Byetta in late 2005 to replace insulin," says Julie W. "Although Charles had type 2 diabetes he was healthy and his diabetes was controlled by a good diet, but Byetta made him lose his appetite and he went downhill from there." Julie knows about the association between Byetta and acute pancreatitis, but Charles died from pancreatic cancer. "I'll blame his death on Byetta for the rest of my life." More>>>
Concerns About Byetta Deaths Lead Amylin to Cut Work Force
-AboutLawsuits
11/23/2008- Amylin Pharmaceuticals announced yesterday that they are cutting their work force by 25 percent following unexpectedly slumping sales for their once promising diabetes drug Byetta, which has recently been associated with 6 deaths caused by severe cases of pancreatitis. More>>>
Is Byetta the Next Rezulin or Avandia – Yet Another Promising Drug That Faces Demise
-InjuryBoard
11/23/2008- Those of us who have personally seen the devastating impact of diabetes in our own lives and those of our loved ones are always looking for the next great drug that might provide hope to our diabetic family members. More>>>